5 research outputs found
SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation
Background. The identification of new
prognostic markers in prostate cancer (PC) is essential to
improve patient treatment and management. Data
suggest that SMARCC1 protein, a part of the
intranuclear SWI/SNF complex which enhances the
transactivation of the androgen receptor, is upregulated
in PC and therefore a possible candidate marker for PC
progression. Materials. Expression of SMARCC1
immunostaining was analysed on a tissue microarray
containing specimens from 327 patients with prostate
cancer and clinical follow-up information. Furthermore,
30 specimens from patients with benign prostate
hyperplasia were included as controls as well as 30
specimens of benign prostate tissue from PC patients.
Also, 18 specimens from lymph node metastases were
analysed. Results. All benign specimens showed no or
minimal staining for SMARCC1. In contrast, 20% of the
specimens from patients with non-metastatic and nonrecurrent
disease showed moderate to marked staining.
In 31% of the patients with recurrent disease and in 31%
of the patients with metastatic disease we found
moderate to strong SMARCC1 immunostaining. In total,
23% of lymph node metastases expressed SMARCC1.
SMARCC1 expression was also positively correlated to Gleason score (p<0.05), clinical T stage (p<0.01) and
time to recurrence (p<0.001). In a logistic regression
analysis, patients with a marked SMARCC1
immunostaining had a significantly elevated odds ratio
(OR) of 16 for recurrent cancer and an OR of 4.5 for
metastatic disease. Conclusions. Our present results
demonstrate an increased expression of SMARCC1
protein in prostate cancer and reveal a positive correlation with tumour dedifferentiation, progression,
metastasis and time to recurrence